Uriel Bohn

498 total citations
16 papers, 253 citations indexed

About

Uriel Bohn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Uriel Bohn has authored 16 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Uriel Bohn's work include Colorectal Cancer Treatments and Studies (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Uriel Bohn is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Uriel Bohn collaborates with scholars based in Spain, United States and Switzerland. Uriel Bohn's co-authors include Antonio González-Martı́n, Jaime Feliú, Gustavo Catalán, Eva Ciruelos, Roser Ferrer, Joan Maurel, P. Escudero, Kathryn P. Gray, Prudence A. Francis and R. Pérez-Carrión and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Uriel Bohn

15 papers receiving 247 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uriel Bohn Spain 9 144 96 85 68 48 16 253
Maura A. Koszalka United States 7 229 1.6× 120 1.3× 25 0.3× 54 0.8× 38 0.8× 8 350
Alan Mackay United Kingdom 7 114 0.8× 31 0.3× 37 0.4× 55 0.8× 19 0.4× 13 254
Ornella Nicoletto Italy 9 69 0.5× 39 0.4× 41 0.5× 35 0.5× 11 0.2× 15 180
A. DeMichele United States 8 109 0.8× 17 0.2× 40 0.5× 83 1.2× 5 0.1× 39 193
Justin A. Drake United States 12 182 1.3× 16 0.2× 130 1.5× 46 0.7× 26 0.5× 25 378
Zorka Inić Serbia 5 92 0.6× 16 0.2× 29 0.3× 69 1.0× 14 0.3× 16 183
Sara Hafezi‐Bakhtiari Canada 9 132 0.9× 20 0.2× 86 1.0× 32 0.5× 6 0.1× 24 264
Erik Asmus United States 6 100 0.7× 29 0.3× 41 0.5× 36 0.5× 55 1.1× 9 179
Rosaria Cesaraccio Italy 10 139 1.0× 30 0.3× 51 0.6× 76 1.1× 19 0.4× 14 243
Nicoletta Provinciali Italy 9 175 1.2× 48 0.5× 54 0.6× 119 1.8× 9 0.2× 22 308

Countries citing papers authored by Uriel Bohn

Since Specialization
Citations

This map shows the geographic impact of Uriel Bohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uriel Bohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uriel Bohn more than expected).

Fields of papers citing papers by Uriel Bohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uriel Bohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uriel Bohn. The network helps show where Uriel Bohn may publish in the future.

Co-authorship network of co-authors of Uriel Bohn

This figure shows the co-authorship network connecting the top 25 collaborators of Uriel Bohn. A scholar is included among the top collaborators of Uriel Bohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uriel Bohn. Uriel Bohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
García‐Albéniz, Xabier, Vicente Alonso, P. Escudero, et al.. (2019). Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). The Oncologist. 24(11). e1115–e1122. 13 indexed citations
2.
Fidalgo, José Alejandro Pérez, María Iglesias, Uriel Bohn, et al.. (2019). GEICO1601-ROLANDO: A Multicentric Single Arm Phase II Clinical Trial to Evaluate the Combination of Olaparib and Pegylated Liposomal Doxorubicin for Platinum-Resistant Ovarian Cancer. Future Science OA. 5(2). FSO370–FSO370. 8 indexed citations
3.
4.
Capdevila, Jaume, José Trigo, Javier Aller, et al.. (2017). Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). European Journal of Endocrinology. 177(4). 309–317. 29 indexed citations
5.
Pineda, Estela, Antonieta Salud, Jorge Aparicio, et al.. (2017). Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumor Biology. 39(6). 3726132150–3726132150. 7 indexed citations
6.
7.
Feliú, Jaime, Antonieta Salud, María José Safont, et al.. (2015). Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. PLoS ONE. 10(1). e0116527–e0116527. 34 indexed citations
8.
Feliú, Jaime, Antonieta Salud, María José Safont, et al.. (2014). First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. British Journal of Cancer. 111(2). 241–248. 22 indexed citations
9.
Capdevila, Jaume, Jose M. Pérez, Javier Aller, et al.. (2014). Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).. Journal of Clinical Oncology. 32(15_suppl). 6027–6027. 9 indexed citations
10.
Bohn, Uriel, et al.. (2008). 131Jod-Therapie des autonomen Adenoms der Schilddrüse: Ergebnisse aus 7 Jahren*. DMW - Deutsche Medizinische Wochenschrift. 112(27). 1073–1079.
11.
Cabrera‐Andrade, Alejandro, et al.. (2005). The androgen receptor gene polymorphisms in human breast cancer: short CAG repeats are associated with lymph node involvement. Acceda (Universidad de Las Palmas de Gran Canaria). 1 indexed citations
12.
Aguiar, David, et al.. (2004). Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 55(2). 152–158. 6 indexed citations
13.
Cassinello, Javier, et al.. (2003). Phase II Study of Weekly Irinotecan (CPT-11) as Second-Line Treatment of Patients with Advanced Colorectal Cancer. Medical Oncology. 20(1). 37–44. 7 indexed citations
14.
Bohn, Uriel, Cristina Bilbao, A Murias, et al.. (2002). Prognostic value of the quantitative measurement of the oncoprotein p185Her‐2/neu in a group of patients with breast cancer and positive node involvement. International Journal of Cancer. 101(6). 539–544. 8 indexed citations
15.
Bohn, Uriel, et al.. (2002). Adverse anaphilactoid reaction of oxaloplatin. 4(3). 159–161. 1 indexed citations
16.
Barthels, M., et al.. (1999). Factor VIII Inhibitor–Tests Could Be Less Sensitive Than Supposed. Vox Sanguinis. 77(Suppl. 1). 87–89. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maura A. Koszalka Breakdown of academic impact, for papers by Alan Mackay Breakdown of academic impact, for papers by Ornella Nicoletto Breakdown of academic impact, for papers by A. DeMichele Breakdown of academic impact, for papers by Justin A. Drake Breakdown of academic impact, for papers by Zorka Inić Breakdown of academic impact, for papers by Sara Hafezi‐Bakhtiari Breakdown of academic impact, for papers by Erik Asmus Breakdown of academic impact, for papers by Rosaria Cesaraccio Breakdown of academic impact, for papers by Nicoletta Provinciali
Rankless by CCL
2026